There are currently 1519 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Recruiting
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland
Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
Recruiting
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/29/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Recruiting
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have metabolic dysfunction-associated steatohepatitis (MASH). MASH is a form of metabolic dysfunction-associated steatotic liver disease (MASLD). MASH occurs when fat builds up in liver cells, damaging them, and making the liver inflamed and stiff from fibrosis (scar tissue). MASH can progress to cirrhosis (long term scarring) and liver failure (when the liver ca... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/29/2025
Locations: Mercy Medical Center, Baltimore, Maryland
Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH)
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
Recruiting
Early detection of coronary atherosclerotic disease facilitates adequate prevention. The purpose of this study is to compare an assessment of coronary atherosclerotic disease burden by positron emission tomography / computed tomography (NaF-PET/CT) with those of conventional and ultra-high-resolution-CT (UHR-CT) in patients with suspected coronary artery disease. For this purpose, the investigators plan to include 33 patients with symptoms concerning for CAD who have been referred for cardiac CT... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Coronary Artery Disease, Atherosclerosis, Coronary Atherosclerosis of Native Coronary Artery
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Recruiting
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
07/29/2025
Locations: University Of Maryland Med Ctr, Baltimore, Maryland
Conditions: Systemic Lupus Erythematosus
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Recruiting
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/29/2025
Locations: Research Site, Baltimore, Maryland
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
Recruiting
This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection. The comparator in this study will be 24-weeks of delayed treatment. During the 24-weeks of delayed treatment, participants will complete the same visits and assessments as those randomized to initiate brelovitug immediately. At the completion of 24-week delayed treatment period, all participants will start treatment w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Baltimore, Baltimore, Maryland
Conditions: Chronic Hepatitis D Infection
Registry for Stage 2 Type 1 Diabetes
Recruiting
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Johns Hopkins School of Medicine- Site Number : 8400031, Baltimore, Maryland
Conditions: Type 1 Diabetes
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) MASH
Recruiting
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/29/2025
Locations: Mercy Medical Center - Baltimore, Maryland, Baltimore, Maryland
Conditions: Metabolic Dysfunction-Associated Steatohepatitis
Post Market Evaluation of Clinical Safety and Performance of the Fitbone Transport and Lengthening System
Recruiting
This is an open-label, prospective, observational, post-market, uncontrolled, multi-center study intended to evaluate the safety and clinical performance of the FITBONE Transport and Lengthening Nail when used according to the manufacturer's Instructions for Use. The FITBONE Transport \& Lengthening Nail is a variant of the FITBONE TAA Nail, which has been commercially available in the US since 2017. The clinical performance and safety of the medical device have been assessed based on mechanical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland
Conditions: Fractures, Bone, Fractures, Closed, Fractures, Open, Fracture of Femur, Fracture Nonunion, Fracture of Tibia, Limb Deformity, Limb Fracture, Limb Defect, Limb Asymmetry
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/28/2025
Locations: Akero Clinical Study Site, Baltimore, Maryland
Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
Recruiting
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
Gender:
ALL
Ages:
Between 3 years and 75 years
Trial Updated:
07/28/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Severe Aplastic Anemia